Table 1. Clinical characteristics of patients.
| Clinical characteristics | N(%)/median(IQR25-75) |
|---|---|
| Number of patients | 500 |
| Age (years) | 58 (47–66) |
| Sex | |
| Male | 309 (61.8) |
| Female | 191 (38.2) |
| Heart failure etiology | |
| Dilated cardiomyopathy | 141 (28.2) |
| Ischemic heart disease | 137 (27.4) |
| Chagas heart disease | 113 (22.6) |
| Hypertension | 56 (11.2) |
| Valvular heart disease | 28 (5.6) |
| Others | 25 (5.0) |
| Admission diagnosis | |
| Progressive heart failure | 303 (60.6) |
| Cardiogenic shock | 62 (12.4) |
| Arrhythmia/Syncope | 53 (10.6) |
| Acute coronary syndrome | 22 (4.4) |
| Infections | 15 (3.0) |
| Others | 45 (9.0) |
| Duration of symptoms (days) | 10 (3–31) |
| Previous history | |
| Arterial hypertension | 262 (52.4) |
| Atrial fibrillation | 179 (35.8) |
| Diabetes Mellitus | 156 (31.2) |
| Previous VT/VF | 68 (13.6) |
| LV ejection fraction (%) | 26 (22–35) |
| Medications | |
| Beta-blocker | 397 (79.4) |
| ACE inhibitor/AT blocker | 312 (62.4) |
| Spironolactone | 269 (53.8) |
| Diuretics | 377 (75.4) |
| Digoxin | 115 (23) |
| Ivabradine | 8 (1.6) |
| Warfarin | 135 (27) |
| Inotropes | 148 (29.6) |
| Creatinine (mg/dL) | 1.65 (1.23–2.34) |
| Brain natriuretic peptide (pg/dL) | 1086 (463–2028) |
| Implantable defibrillator | 59 (11.8) |
LV: left ventricle; VT: ventricular tachycardia; VF: ventricular fibrillation; ACE: angiotensin-converting enzyme